Cynata Therapeutics Revenue
Biotechnology Research • 
Melbourne, Victoria, Australia • 1-10 Employees
Cynata Therapeutics revenue & valuation
| Annual revenue | $5,396,319 |
| Revenue per employee | $540,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $17,300,000 |
| Total funding | $1,000,000 |
Key Contacts at Cynata Therapeutics
Kilian Kelly
Chief Executive Officer And Managing Director
Anna Hanks
Associate Director Clinical Operations
Company overview
| Headquarters | 100 Cubitt St, L3, Cremorne, Victoria 3121, AU |
| Phone number | +61370676940 |
| Websites | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Stem Cells, Ipscs, Mscs |
| Employees | 1-10 |
| Socials |
Cynata Therapeutics Email Formats
Cynata Therapeutics uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@cynata.com), used 87.5% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@cynata.com | 87.5% |
{first name}.{last name} | john.doe@cynata.com | 12.5% |
About Cynata Therapeutics
Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors. Cynata’s lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Clinical trials of Cymerus MSC products in osteoarthritis (Phase 3) and in severe complications arising from COVID-19 (Phase 2) are currently ongoing. Planning is also underway for further clinical trials of Cymerus MSC products in GvHD (through licensee Fujifilm), critical limb ischemia, idiopathic pulmonary fibrosis, renal transplantation, and diabetic foot ulcers. In addition, Cynata has demonstrated utility of its Cymerus MSC technology in preclinical models of numerous diseases, including the clinical targets mentioned above, as well as asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
Cynata Therapeutics has 4 employees across 4 departments.
Departments
Number of employees
Cynata Therapeutics Tech Stack
Discover the technologies and tools that power Cynata Therapeutics's digital infrastructure, from frameworks to analytics platforms.
CDN
CDN
Security
JavaScript libraries
JavaScript libraries
Tag managers
Advertising
Reverse proxies
Miscellaneous
UI frameworks
Video players
United Kingdom
Egypt
United States
Colombia
Korea, Republic of
Frequently asked questions
4.8
40,000 users
